Press Releases

MENLO PARK, Calif. , Nov. 11, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following upcoming investor conferences:     Canaccord Genuity MedTech, Diagnostics and Digital

MENLO PARK, Calif. , Nov. 7, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2022 .     Third quarter results Revenue of $32.3 million , a 7% decrease compared with $34.9 million in the prior year period.

 World Class Team Will Provide Strategic Guidance and Direction for PacBio's Research and Development Activities MENLO PARK, Calif. , Nov. 2, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced it is bringing

Significant Advances in SMRT Cell Design, Compute, and a New System Architecture Will Enable Revio to Dramatically Increase Throughput and Lower Cost  While Leveraging the Power of HiFi for Exceptional Accuracy and Direct Methylation Detection MENLO PARK, Calif. , Oct.

The Onso Sequencing System is Designed to Deliver Industry-Leading Sensitivity and Specificity for Novel Insights in Oncology and Disease Research MENLO PARK, Calif. , Oct. 25, 2022 /PRNewswire/ -- PacBio  (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions,

Withdraws Guidance with New Product Announcement MENLO PARK, Calif. , Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2022 financial results on Monday, Nov. 7, 2022 , at 5:00 p.m. Eastern Time .

MAS-Seq Supports Isoform Research Using Single-Cell RNA Sequencing from 10x Genomics MENLO PARK, Calif. , Oct. 20, 2022 /PRNewswire/ -- PacBio  (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the launch of its Multiplexed Arrays Sequencing

Alliance panels include a 50-gene pharmacogenomics panel and a nearly 400-gene panel of challenging, medically relevant "dark genes" developed in collaboration with leading institutions MENLO PARK, Calif. and SOUTH SAN FRANCISCO , Oct. 19, 2022 /PRNewswire/ -- PacBio  (NASDAQ: PACB), a leading

The Consortium Will Build a Publicly Available Database as a Resource to Accelerate Insights from Long-Read Human Genome Datasets MENLO PARK, Calif. , Oct. 18, 2022 /PRNewswire/ -- PacBio  (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the

Analysis Method Supports Research on the Genetic Causes of Common Diseases MENLO PARK, Calif. , Sept. 27, 2022 /PRNewswire/ --  PacBio  (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the availability of a new computational analysis method